Drugs List

Therapeutic Indications

Uses

Allergy - diagnosis of allergen sensitivity

Contraindications

Children under 1 year
Dermatitis

Precautions and Warnings

Children aged 1 to 4 years
Pregnancy

Treatment to be initiated and supervised by a specialist
Withhold antihistamines therapy following manufacturer's instructions
Withhold potent topical steroids 2 to 3 weeks prior to the test
Avoid administration to eczematous or inflamed skin
Avoid areas with skin lesions
Have adrenaline injection ready for use in case of anaphylaxis
Beta blockers may reduce the response to adrenaline in anaphylaxis

Pregnancy and Lactation

Pregnancy

Caution should be used in pregnancy.

The manufacturer notes that the risk of performing skin-prick test during pregnancy must be carefully evaluated together with the patient in order to identify the specific clinical need for identifying the trigger allergen during the period of pregnancy.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

The manufacturer notes that this skin-prick test may be performed during lactation.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Side Effects

Anaphylactic reaction
Erythema at application site
Itching sensation (local)
Local pain
Swelling(localised)

Presentation

This skin prick test contains a dual pack, one is Positive and the other is Negative

The Positive pack contains histamine dihydrochloride solution

The Negative pack contains no active ingredient

Drugs List

Therapeutic Indications

Uses

Allergy - diagnosis of allergen sensitivity

Dosage

The Positive control is applied as reference to evaluate the general reactivity of the skin-prick test.

The Negative control test is applied to evaluate unspecific reactions.

The skin-prick test may be performed on the volar side of the forearm or on the back.

Adults

Elderly

Children

Additional Dosage Information

Contraindications

Children under 1 year
Dermatitis

Precautions and Warnings

Children aged 1 to 4 years
Pregnancy

Treatment to be initiated and supervised by a specialist
Withhold antihistamines therapy following manufacturer's instructions
Withhold potent topical steroids 2 to 3 weeks prior to the test
Avoid administration to eczematous or inflamed skin
Avoid areas with skin lesions
Have adrenaline injection ready for use in case of anaphylaxis
Beta blockers may reduce the response to adrenaline in anaphylaxis

Pregnancy and Lactation

Pregnancy

Caution should be used in pregnancy.

The manufacturer notes that the risk of performing skin-prick test during pregnancy must be carefully evaluated together with the patient in order to identify the specific clinical need for identifying the trigger allergen during the period of pregnancy.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

The manufacturer notes that this skin-prick test may be performed during lactation.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Side Effects

Anaphylactic reaction
Erythema at application site
Itching sensation (local)
Local pain
Swelling(localised)

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: December 2013

Reference Sources

Summary of Product Characteristics: Soluprick Controls. ALK-Abello Ltd. Revised June 2011.